Reference 2018-250

REF:           2018-250

Subject:       Provision of free of charge drug stock between licensing and NICE funding

 

 

Request:

  1. Has your trust accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding? [Yes/No]

 

  1. Has your trust accepted or is it currently accepting the following list of drugs in psoriasis:

Brodalumab [Kyntheum]             [Yes/No]

Guselkumab [Tremfya]                 [Yes/No]

Ixekizumab [Taltz]                         [Yes/No]

Secukinumab [Cosentyx]              [Yes/No]

 

  1. Has your trust accepted or is it currently accepting the following list of drugs in Rheumatoid Arthritis:

Tofacitinib [Xeljanz]                      [Yes/No]

Baricitinib [Olumiant]                   [Yes/No]

Golimumab [Simponi]                  [Yes/No]

Certolizumab [Cimzia]                  [Yes/No]

Apremilast [Otezla]                       [Yes/No]

Tocilizumab [Ro Actemra]            [Yes/No]

  1. Has your trust accepted or is it currently accepting the following list of drugs in Ankylosing Spondylitis or Psoriatic Arthritis:

Secukinumab [Cosentyx]             [Yes/No]

 

  1. Has your trust accepted or is it currently accepting the following list of drugs in Ulcerative Colitis:

Golimumab [Simponi]                  [Yes/No]

 

  1. If your trust has not accepted manufacturer provision of free of charge drug stock, what have been the reasons for this? [……………………………..]
  2. In future, will your trust be able to accept manufacturer provision of free of charge drug stock? [Yes/No]
  3. What is the preferred distribution channel for the provision of free of charge drug stock?

Homecare                                                     [Yes/No]

Delivered directly to hospital/Trust         [Yes/No]

Other (please provide details)                  [………………………………………….]

  1. For how long is free of charge drug stock typically provided for each patient ?

first dose                                         [Yes/No]

first month                                     [Yes/No]

first 3 months                                [Yes/No]

Other   [………………………………..]

 

 

Response:

1. Has your trust accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding? [Yes/No] No
2. Has your trust accepted or is it currently accepting the following list of drugs in psoriasis: Brodalumab[Kyntheum] No
Guselkumab[Tremfya] No
Ixekizumab [Taltz] No
Secukinumab [Cosentyx] No
3. Has your trust accepted or is it currently accepting the following list of drugs in Rheumatoid Arthritis: Tofacitinib[Xeljanz] No
Baricitinib[Olumiant] No
Golimumab[Simponi] No
Certolizumab[Cimzia] No
Apremilast[Otezla] No
Tocilizumab[RoActemra] No
4. Has your trust accepted or is it currently accepting the following list of drugs in Ankylosing Spondylitis or Psoriatic Arthritis: Secukinumab[Cosentyx] No
 5. Has your trust accepted or is it currently accepting the following list of drugs in Ulcerative Colitis: Golimumab[Simponi] No
6. If your trust has not accepted manufacturer provision of free of charge drug stock, what have been the reasons for this?[ No requirement to access FOC scheme
7. In future, will your trust be able to accept manufacturer provision of free of charge drug stock? [Yes/No] FOC stock will be in line with GMMMG position.
8. What is the preferred distribution channel for the provision of free of charge drug stock? Homecare N/A
Delivered directly to hospital/Trust N/A
Other (please provide details) N/A
9. For how long is free of charge drug stock typically provided for each patient ?

first dose                                         [Yes/No] –

first month                                     [Yes/No]-

first 3 months                                [Yes/No]-

Other   [………………………………..]

N/A